Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes With del5q, Refractory/Resistant/Intolerant to Prior Treatments, Who Require Red Blood Cell Transfusions

NCT05924100 is registered in ClinicalTrials.gov with Associazione Qol-one as lead sponsor.

NCT NCT05924100
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05924100 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes With del5q, Refractory/Resistant/Intolerant to Prior Treatments, Who Require Red Blood Cell Transfusions
Lead sponsor
Associazione Qol-one
Phase
Phase 2
Overall status
Recruiting
Start date
November 3, 2022
Completion date
December 3, 2029
Enrollment
22 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, del(5q), myelodysplastic syndromes, transfusion-dependent anemia